Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630
Ariel Yung-Chia Chen(Revolution Medicines (United States)), Pasi A. Jänne(Harvard University), Elsa Quintana(Revolution Medicines (United States)), Judy S. Wang(Sarah Cannon), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Martha Guerra(Revolution Medicines (United States)), Richa Dua(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Eric B. Haura(Moffitt Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Howard A. Burris(Deaconess Hospital), Jonathan W. Riess(University of California Davis Medical Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Josie Hayes(University of California, Berkeley), Xiaolin Wang(University of Toronto), Hongfang Wang(Memorial Sloan Kettering Cancer Center), Jose M. Pacheco(University of Colorado Cancer Center), Bojena Bitman(Revolution Medicines (United States)), Anna Capasso(The University of Texas at Austin), Marianna Koczywas(City Of Hope National Medical Center)
Cited by 3
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k